Citations

Clear

626 citation(s) found for "Mehta, SH".

SARS-CoV-2 direct cardiac damage through spike-mediated cardiomyocyte fusion
Schneider, Jay W. , Pease, David R. , Clemens, Daniel J. , Ye, Dan , Kim, Changsung, Barkhymer, Alison , Cohle, Stephen D., Banks, Aron, Mehta, Arpit, Rantus, Joseph, Emmerzaal, Tim L. , Howell, Kyle G., Charlesworth, Jon E. , Christensen, Trace , Kawaoka, Yoshihiro , Cooper, Leslie, Cattaneo, Roberto , Schneider, Jay W , Navaratnarajah, Chanakha K. , Halfmann, Peter , Kim, Changsung, Kozicz, Tamás , Ackerman, Michael

Mayo Clinic

No container title available | October 30, 2020 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-95587/v1 Get It

Abstract Viruses spread between hosts through particles, but within hosts, viral genomes can spread from cell to cell through fusion, evading antiviral defenses and obviating costly infectious virion production1-3. Billions of electromechanically coupled cardiomyocytes (CMs) make myocardium inherently vulnerable to pathological electromechanical short circuits caused by intercellular viral spread 4-6. Beyond respiratory illness, COVID-19 affects the heart7 and cardiac injury and arrhythmias are serious public health concerns8-12. By studying myocardium of a young woman who died suddenly, diagnosed postmortem with COVID-19, we discovered highly focal myocardial SARS-CoV-2 infection spreading from one CM to another through intercellular junctions identified by highly concentrated sarcolemmal t-tubule viral spike glycoprotein. SARS-CoV-2 permissively infected beating human induced pluripotent stem cell (hiPSC)-CMs building multinucleated cardiomyotubes (CMTs) through cell type-specific fusion driven by proteolytically-activated spike glycoprotein. Recombinant spike glycoprotein, co-localizing to sarcolemma and sarcoplasmic reticulum, produced multinucleated CMTs with pathological structure, electrophysiology and Ca2+ excitation-contraction coupling. Blocking cleavage, a peptide-based protease inhibitor neutralized SARS-CoV-2 spike glycoprotein pathogenicity. We conclude that SARS-CoV-2 spike glycoprotein, efficiently primed, activated and strategically poised during biosynthesis, can exploit the CM’s inherent membranous connectivities to drive heart damage directly, uncoupling clinically common myocardial injury from lymphocytic myocarditis, often suspected but rarely confirmed in COVID-19.
Childhood Sjögren syndrome: features of an international cohort and application of the 2016 ACR/EULAR classification criteria
Basiaga, Matthew L. , Stern, Sara , Edens, Cuoghi , Randell, Rachel L. , Pomorska, Anna , Ibarra, Maria, Nicolai, Rebecca , Sušić, Gordana , Boneparth, Alexis , Dizon, Brian , Kamdar, Ankur, Goldberg, Baruch R., Knupp-Oliveira, Sheila, Mosquera, Juan Manuel , Appenzeller, Simone , O’Neil, Kathleen M., Protopapas, Stella , Saad‐Magalhães, Claudia , Akikusa, Jonathan , Thatayatikom, Akaluck , Cha, Seunghee , Nieto‐González, Juan Carlos , Lo, Mindy S. , Lieberman, Scott M. , Randell, Rachel L , Mehta, Jay , Irga‐Jaworska, Ninela , Bracaglia, Claudia , Srinivasalu, Hemalatha , Antón, Jordi , Treemarcki, Erin , Yokogawa, Naoto

Mayo Clinic

Rheumatology | October 28, 2020 | Volume: 60 | Issue: 7 | Pages: 3144-3155

10.1093/rheumatology/keaa757 | PMID 33280020 Get It

Abstract Objective Sjögren syndrome in children is a poorly understood autoimmune disease. We aimed to describe the clinical and diagnostic features of children diagnosed with Sjögren syndrome and explore how the 2016 ACR/EULAR classification criteria apply to this population. Methods An international workgroup retrospectively collected cases of Sjögren syndrome diagnosed under 18 years of age from 23 centres across eight nations. We analysed patterns of symptoms, diagnostic workup, and applied the 2016 ACR/EULAR classification criteria. Results We identified 300 children with Sjögren syndrome. The majority of patients n = 232 (77%) did not meet 2016 ACR/EULAR classification criteria, but n = 110 (37%) did not have sufficient testing done to even possibly achieve the score necessary to meet criteria. Even among those children with all criteria items tested, only 36% met criteria. The most common non-sicca symptoms were arthralgia [n = 161 (54%)] and parotitis [n = 140 (47%)] with parotitis inversely correlating with age. Conclusion Sjögren syndrome in children can present at any age. Recurrent or persistent parotitis and arthralgias are common symptoms that should prompt clinicians to consider the possibility of Sjögren syndrome. The majority of children diagnosed with Sjögren syndromes did not meet 2016 ACR/EULAR classification criteria. Comprehensive diagnostic testing from the 2016 ACR/EULAR criteria are not universally performed. This may lead to under-recognition and emphasizes a need for further research including creation of paediatric-specific classification criteria.
Subsequent urinary stone events are predicted by the magnitude of urinary oxalate excretion in enteric hyperoxaluria
D’Costa, Matthew R. , Kausz, Annamaria T., Carroll, Kevin J., Ingimarsson, Johann P. , Mara, Kristin C. , Mehta, Ramila A. , Enders, Felicity T, D'Costa, Matthew , Mara, Kristin C , Enders, Felicity , Lieske, John C.

Mayo Clinic

Nephrology Dialysis Transplantation | October 14, 2020 | Volume: 36 | Issue: 12 | Pages: 2208-2215

10.1093/ndt/gfaa281 | PMID 33367720 Get It

Abstract Data directly demonstrating the relationship between urinary oxalate (UOx) excretion and stone events in those with enteric hyperoxaluria (EH) are limited. Therefore, we assessed the relationship between UOx excretion and risk of kidney stone events in a retrospective population-based EH cohort. In all, 297 patients from Olmsted County, Minnesota were identified with EH based upon having a 24-h UOx ≥40 mg/24 h preceded by a diagnosis or procedure associated with malabsorption. Diagnostic codes and urologic procedures consistent with kidney stones during follow-up after baseline UOx were considered a new stone event. Logistic regression and accelerated failure time modeling were performed as a function of UOx excretion to predict the probability of new stone event and the annual rate of stone events, respectively, with adjustment for urine calcium and citrate. Mean ± standard deviation age was 51.4 ± 11.4 years and 68% were female. Median (interquartile range) UOx was 55.4 (46.6–73.0) mg/24 h and 81 patients had one or more stone event during a median follow-up time of 4.9 (2.8–7.8) years. Higher UOx was associated with a higher probability of developing a stone event (P < 0.01) and predicted an increased annual risk of kidney stones (P = 0.001). Estimates derived from these analyses suggest that a 20% decrease in UOx is associated with 25% reduction in the annual odds of a future stone event. Thus, these data demonstrate an association between baseline UOx and stone events in EH patients and highlight the potential benefit of strategies to reduce UOx in this patient group. Background Data directly demonstrating the relationship between urinary oxalate (UOx) excretion and stone events in those with enteric hyperoxaluria (EH) are limited. Methods We assessed the relationship between UOx excretion and risk of kidney stone events in a retrospective population-based EH cohort. In all, 297 patients from Olmsted County, Minnesota were identified with EH based upon having a 24-h UOx ≥40 mg/24 h preceded by a diagnosis or procedure associated with malabsorption. Diagnostic codes and urologic procedures consistent with kidney stones during follow-up after baseline UOx were considered a new stone event. Logistic regression and accelerated failure time modeling were performed as a function of UOx excretion to predict the probability of new stone event and the annual rate of stone events, respectively, with adjustment for urine calcium and citrate. Results Mean ± SD age was 51.4 ± 11.4 years and 68% were female. Median (interquartile range) UOx was 55.4 (46.6–73.0) mg/24 h and 81 patients had ≥1 stone event during a median follow-up time of 4.9 (2.8–7.8) years. Higher UOx was associated with a higher probability of developing a stone event (P < 0.01) and predicted an increased annual risk of kidney stones (P = 0.001). Estimates derived from these analyses suggest that a 20% decrease in UOx is associated with 25% reduction in the annual odds of a future stone event. Conclusions These data demonstrate an association between baseline UOx and stone events in EH patients and highlight the potential benefit of strategies to reduce UOx in this patient group.
When Should Asymptomatic Persons Be Tested for COVID-19?
Schuetz, Audrey N. , Mehta, Ninad , Campbell, Sheldon , Mitchell, Stephanie L. , Palavecino, Elizabeth , Butler‐Wu, Susan M. , Mehta, Ninad , Mitchell, Stephanie , Butler-Wu, Susan , Schuetz, Audrey N , Hemarajata, Peera , Miller, Melissa B.

Mayo Clinic

Journal of Clinical Microbiology | October 7, 2020 | Volume: 59 | Issue: 1 | Pages: No page available

10.1128/jcm.02563-20 | PMID 33023910 Get It

On 24 August 2020, the Centers for Disease Control and Prevention (CDC) updated its website to highlight that asymptomatic individuals, even those with exposure to a COVID-19-positive contact, do not necessarily need to be tested unless they have medical conditions associated with increased risk of severe illness from COVID-19. The CDC subsequently updated its guidance on 19 September 2020 to support testing of asymptomatic persons, including close contacts of persons with documented SARS-CoV-2 infection.
NCCN Guidelines Insights: Colorectal Cancer Screening, Version 2.2020
Provenzale, Dawn, Llor, Xavier , Abbadessa, Benjamin, Cooper, Gregory S. , Early, Dayna S., Friedman, Mark , Giardiello, Francis M., Glaser, Kathryn , Gurudu, Suryakanth, Halverson, Amy L. , Issaka, Rachel B. , Jain, Rishi , Kidambi, Trilokesh D. , Lazenby, Audrey J., Markowitz, Arnold J. , May, Folasade P. , Mehta, Shivan J. , Peter, Shajan , Stanich, Peter P. , Terdiman, Jonathan P., Keller, Jennifer , Dwyer, Mary A., Ogba, Ndiya , Ness, Reid M. , Weiss, Jennifer M. , Kanth, Priyanka , Maguire, Lillias Holmes , Mayer, Robert J. , Patel, Swati

Mayo Clinic

Journal of the National Comprehensive Cancer Network | October 6, 2020 | Volume: 18 | Issue: 10 | Pages: 1312-1320

10.6004/jnccn.2020.0048 | PMID 33022639 Get It

The NCCN Guidelines for Colorectal Cancer (CRC) Screening describe various colorectal screening modalities as well as recommended screening schedules for patients at average or increased risk of developing sporadic CRC. They are intended to aid physicians with clinical decision-making regarding CRC screening for patients without defined genetic syndromes. These NCCN Guidelines Insights focus on select recent updates to the NCCN Guidelines, including a section on primary and secondary CRC prevention, and provide context for the panel’s recommendations regarding the age to initiate screening in average risk individuals and follow-up for low-risk adenomas.
Digital Health and the Care of the Patient With Arrhythmia
Tarakji, Khaldoun G. , Silva, Jennifer N. Avari , Turakhia, Mintu P. , Pérez, Marco , Attia, Zachi I. , Passman, Rod , Boissy, Adrienne , Cho, David , Majmudar, Maulik D. , Chung, Mina K. , Attia, Zachi I , Passman, Rod , Turakhia, Mintu P , Perez, Marco V , Chen, Lin Y. , Mehta, Neil , Wan, Elaine Y.

Mayo Clinic

Circulation: Arrhythmia and Electrophysiology | October 6, 2020 | Volume: 13 | Issue: 11 | Pages: No page available

10.1161/circep.120.007953 | PMID 33021815 Get It

The field of cardiac electrophysiology has been on the cutting edge of advanced digital technologies for many years. More recently, medical device development through traditional clinical trials has been supplemented by direct to consumer products with advancement of wearables and health care apps. The rapid growth of innovation along with the mega-data generated has created challenges and opportunities. This review summarizes the regulatory landscape, applications to clinical practice, opportunities for virtual clinical trials, the use of artificial intelligence to streamline and interpret data, and integration into the electronic medical records and medical practice. Preparation of the new generation of physicians, guidance and promotion by professional societies, and advancement of research in the interpretation and application of big data and the impact of digital technologies on health outcomes will help to advance the adoption and the future of digital health care.
Survival in Patients With Brain Metastases: Summary Report on the Updated Diagnosis-Specific Graded Prognostic Assessment and Definition of the Eligibility Quotient
Sperduto, Paul W. , Mesko, Shane , Li, Jing , Cagney, Daniel , Aizer, Ayal A. , Lin, Nancy U. , Nesbit, Eric , Chan, Jason W., Braunstein, Steve , Breen, Will, Brown, Paul D. , Shi, Diana D. , Soliman, Hany , Sahgal, Arjun , Shanley, Ryan , Sperduto, William , Everett, Ashlyn S. , Boggs, Drexell H. , Masucci, Laura , Plichta, Kristin A. , Buatti, John M. , Jain, Supriya , Gaspar, Laurie E., Wu, Cheng–Chia , Wang, Tony J. C. , Bryant, John , Chuong, Michael D. , An, Yi , Chiang, Veronica , Nakano, Toshimichi , Aizer, Ayal , Chan, Jason , Braunstein, Steve , Breen, Will , Brown, Paul D , Shi, Diana , Shih, Helen A , Shanley, Ryan , Lou, Emil , Everett, Ashlyn , Boggs, Drexell H , Buatti, John M , Jain, Supriya , Wang, Tony J C , Chuong, Michael , An, Yi , Chiang, Veronica , Nakano, Toshimichi , Mehta, Minesh P , Lin, Nancy U , Kruser, Tim J. , Lee, Jessica , Kirkpatrick, John P. , Shih, Helen A. , Lou, Emil , Roberge, David , Remick, Jill S. , Aoyama, Hidefumi , Mehta, Minesh P.

Mayo Clinic

Journal of Clinical Oncology | September 15, 2020 | Volume: 38 | Issue: 32 | Pages: 3773-3784

10.1200/jco.20.01255 | PMID 32931399 Get It

PURPOSE Conventional wisdom has rendered patients with brain metastases ineligible for clinical trials for fear that poor survival could mask the benefit of otherwise promising treatments. Our group previously published the diagnosis-specific Graded Prognostic Assessment (GPA). Updates with larger contemporary cohorts using molecular markers and newly identified prognostic factors have been published. The purposes of this work are to present all the updated indices in a single report to guide treatment choice, stratify research, and define an eligibility quotient to expand eligibility. METHODS A multi-institutional database of 6,984 patients with newly diagnosed brain metastases underwent multivariable analyses of prognostic factors and treatments associated with survival for each primary site. Significant factors were used to define the updated GPA. GPAs of 4.0 and 0.0 correlate with the best and worst prognoses, respectively. RESULTS Significant prognostic factors varied by diagnosis and new prognostic factors were identified. Those factors were incorporated into the updated GPA with robust separation ( P < .01) between subgroups. Survival has improved, but varies widely by GPA for patients with non–small-cell lung, breast, melanoma, GI, and renal cancer with brain metastases from 7-47 months, 3-36 months, 5-34 months, 3-17 months, and 4-35 months, respectively. CONCLUSION Median survival varies widely and our ability to estimate survival for patients with brain metastases has improved. The updated GPA (available free at brainmetgpa.com) provides an accurate tool with which to estimate survival, individualize treatment, and stratify clinical trials. Instead of excluding patients with brain metastases, enrollment should be encouraged and those trials should be stratified by the GPA to ensure those trials make appropriate comparisons. Furthermore, we recommend the expansion of eligibility to allow for the enrollment of patients with previously treated brain metastases who have a 50% or greater probability of an additional year of survival (eligibility quotient > 0.50).
Abstract PR05: A meta-analysis of genome-wide association study and eQTL analysis of multiple myeloma among African Americans
Du, Zhaohui , Weinhold, Niels , Song, Gregory, Rand, K.A., Hwang, Amie E. , Sheng, Xin , Hom, Victor, Pawlish, Karen , Peters, Edward , Mohrbacher, Ann, Stram, Alexander , Berndt, Sonja I. , Blot, William J. , Stevens, Victoria L. , Goodman, Phyllis J. , Hennis, Anselm , Nemesure, Barbara , Stanford, Janet L. , Witte, John S. , Signorello, Lisa B., John, Esther M. , Stroup, Antoinette M. , Zangari, Maurizio , Zheng, Wei , Hu, Jennifer J. , Carpten, John D. , Mehta, Jayesh, Wolf, Jeffrey L. , Martin, Thomas G. , Terebelo, Howard R. , Janakiraman, Nalini, Kolonel, Laurence N. , Auclair, Daniel , Vij, Ravi , Bernal‐Mizrachi, Leon , Zonder, Jeffrey A. , Huff, Carol Ann , Conti, David V. , Haiman, Christopher A. , John, Esther M , Zheng, Wei , Conti, David V , Berg, David Van Den , Ailawadhi, Sikander , Nooka, Ajay K. , Singhal, Seema , Bock, Cathryn Hufford , Stram, Alex , Casey, Graham , Kittles, Rick A. , Diver, W. Ryan , Klein, Eric A. , Rybicki, Benjamin A. , Bernstein, Leslie , Stephens, Owen , Rhee, Frits van , Olshan, Andrew F. , Ziegler, Regina G. , Nyante, Sarah J. , Ingles, Sue A. , Press, Michael F. , Chanock, Stephen Jacob , Colditz, Graham A. , Tomasson, Michael H. , Fiala, Mark A. , Anderson, Kenneth C. , Marchand, Loı̈c Le , Chiu, Brian C.‐H. , Ziv, Elad , Stram, Daniel O. , Morgan, Gareth J. , Lonial, Sagar , Orlowski, Robert Z. , Cozen, Wendy

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | September 1, 2020 | Volume: 29 | Issue: 6_Supplement_2 | Pages: PR05-PR05

10.1158/1538-7755.disp19-pr05 Get It

Abstract Background: Persons of African ancestry (AA) experience a 1.5-2-fold risk of multiple myeloma (MM) compared to persons of European ancestry (EA). We assembled a set of MM patients with self-reported AA in order to evaluate the contribution of genetics to etiology in this high-risk group. Methods: Here we present the results of a meta-analysis of two GWAS in 1,813 cases and 8,871 controls of AA. We also conducted an admixture mapping scan to identify risk alleles associated with local ancestry, fine-mapped the 23 known susceptibility loci to find markers that could better capture MM risk in individuals of AA, and constructed a polygenic risk score (PRS) to assess the aggregated effect of known MM risk alleles. Finally, we conducted an eQTL analysis measuring gene expression in those genes harboring a risk variant in malignant plasma cells from 292 of the patients from a single site. Results: In GWAS analysis, we identified two suggestive novel loci located at 9p24.3 and 9p13.1 at P&lt;1 × 10-6, but no genome-wide significant association was noted. In admixture mapping, we observed a genome-wide significant inverse association between local AA at 2p24.1-23.1 and MM risk in AA individuals. 20 of the 23 known EA risk variants showed directional consistency and 9 replicated at P&lt;0.05 in AA individuals. In eight regions, we identified markers that better capture MM risk in persons of AA. AA individuals with a PRS in the top 10% had a 1.82-fold (95%CI: 1.56, 2.11) increased MM risk compared to those with average risk (25-75%). The strongest functional association was between the risk allele for variant rs56219066 at 5q15 and lower ELL2 expression (P= 5.1 × 10–12). Conclusion: Our study shows that common genetic variation contributes to MM risk individuals of AA. This abstract is also being presented as Poster C040. Citation Format: Zhaohui Du, Niels Weinhold, Gregory Chi Song, Kristen A. Rand, David J. Van Den Berg, Amie E. Hwang, Xin Sheng, Victor Hom, Sikander Ailawadhi, Ajay K. Nooka, Seema Singhal, Karen Pawlish, Edward Peters, Cathryn Bock, Ann Mohrbacher, Alexander Stram, Sonja I. Berndt, William J. Blot, Graham Casey, Victoria L. Stevens, Rick Kittles, Phyllis J. Goodman, W. Ryan Diver, Anselm Hennis, Barbara Nemesure, Eric A. Klein, Benjamin A. Rybicki, Janet L. Stanford, John S. Witte, Lisa Signorello, Esther M. John, Leslie Bernstein, Antoinette Stroup, Owen W. Stephens, Maurizio Zangari, Frits Van Rhee, Andrew Olshan, Wei Zheng, Jennifer J. Hu, Regina Ziegler, Sarah J. Nyante, Sue Ann Ingles, Michael Press, John David Carpten, Stephen Chanock, Jayesh Mehta, Graham A Colditz, Jeffrey Wolf, Thomas G. Martin, Michael Tomasson, Mark A. Fiala, Howard Terebelo, Nalini Janakiraman, Laurence Kolonel, Kenneth C. Anderson, Loic Le Marchand, Daniel Auclair, Brian C.-H. Chiu, Elad Ziv, Daniel Stram, Ravi Vij, Leon Bernal-Mizrachi, Gareth J. Morgan, Jeffrey A. Zonder, Carol Ann Huff, Sagar Lonial, Robert Z. Orlowski, David V. Conti, Christopher A. Haiman, Wendy Cozen. A meta-analysis of genome-wide association study and eQTL analysis of multiple myeloma among African Americans [abstract]. In: Proceedings of the Twelfth AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2019 Sep 20-23; San Francisco, CA. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2020;29(6 Suppl_2):Abstract nr PR05.
Type‐B Diencephalic‐Mesencephalic Junction Dysplasia Initially Presented With Secondary Cough‐Induced Headaches: A Case Report
Mehta, Dev , Swanson, Jerry W., Mehta, Dev G

Mayo Clinic

Headache: The Journal of Head and Face Pain | August 30, 2020 | Volume: 60 | Issue: 10 | Pages: 2600-2602

10.1111/head.13947 | PMID 32862470 Get It